GILEAD SCIENCES, INC. Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions
GILEAD SCIENCES, INC. (GILD) reported Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions of $180.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions · last filed 2026-02-24
- GILEAD SCIENCES, INC. unrecognized tax benefits, increase resulting from current period tax positions for the quarter ending 2024-12-31 was $43.00M.
- GILEAD SCIENCES, INC. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2025 was $180.00M, a 75.77% decline from fiscal 2024.
- GILEAD SCIENCES, INC. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2024 was $743.00M, a 180.38% increase from fiscal 2023.
- GILEAD SCIENCES, INC. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2023 was $265.00M, a 105.43% increase from fiscal 2022.
- GILEAD SCIENCES, INC. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2022 was $129.00M, a 12.24% decline from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions 3 month | Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions 9 month | Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions 12 month | Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions 12 month as first filed |
|---|---|---|---|---|
| 2025-12-31 | $180.00M 10-K · filed 2026-02-24 | |||
| 2024-12-31 | $43.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $743.00M 10-K · filed 2026-02-24 | ||
| 2024-09-30 | $700.00M 10-Q · filed 2024-11-12 | |||
| 2023-12-31 | $265.00M 10-K · filed 2026-02-24 | |||
| 2022-12-31 | $129.00M 10-K · filed 2025-02-28 | |||
| 2021-12-31 | $147.00M 10-K · filed 2024-02-23 | |||
| 2020-12-31 | $121.00M 10-K · filed 2023-02-22 | |||
| 2019-12-31 | $138.00M 10-K · filed 2022-02-23 | |||
| 2018-12-31 | $64.00M 10-K · filed 2021-02-25 | |||
| 2017-12-31 | $299.00M 10-K · filed 2020-02-25 | |||
| 2016-12-31 | $522.00M 10-K · filed 2019-02-26 | |||
| 2015-12-31 | $675.00M 10-K · filed 2018-02-27 | |||
| 2014-12-31 | $430.00M 10-K · filed 2017-02-27 | |||
| 2013-12-31 | $112.00M 10-K · filed 2016-02-24 | $112.20M 10-K · filed 2014-02-25 | ||
| 2012-12-31 | $26.00M 10-K · filed 2015-02-25 | $26.69M 10-K · filed 2013-02-27 | ||
| 2011-12-31 | $21.11M 10-K · filed 2014-02-25 | |||
| 2010-12-31 | $24.32M 10-K · filed 2013-02-27 | |||
| 2009-12-31 | $25.04M 10-K · filed 2012-02-23 | |||
| 2008-12-31 | $37.49M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |